Human Oncology & Pathogenesis Program

The Emily Cheng Lab

Research

Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

The focus of the Cheng laboratory is to elucidate the molecular mechanisms underlying cell death with the hope that the knowledge derived from our research can be translated into targeted therapeutics that trigger cell death in cancer.

View Lab Overview

The Cheng Lab

Publications

Ren D, Tu H, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010 Dec 3;330(6009):1390-3. doi: 10.1126/science.1190217.

Kim H, Rafiuddin-Shah M, Tu HC, Jeffers J, Zambetti GP, Hsieh JJD, Cheng EHY. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol. 2006 Dec;8(12):1348-58. Epub 2006 Nov 19.

Kim H, Tu H, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJD, Cheng EHY. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell. 2009 Nov 13;36(3):487-99. doi: 10.1016/j.molcel.2009.09.030.

Bean GR, Ganesan YT, Dong Y, Takeda S, Liu H, Chan PM, Huang Y, Chodosh LA, Zambetti GP, Hsieh JJD, Cheng EHY. PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal. 2013 Mar 26;6(268):ra20. doi: 10.1126/scisignal.2003483.

Tu HC, Ren D, Wang G, Chen DY, Westergard TD, Kim H, Sasagawa S, Hsieh JJD, Cheng EHY. The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc Natl Acad Sci USA 2009; 106:1093-1098.

View All Publications

People

Emily H. Cheng, MD, PhD

Attending Pathologist, Department of Pathology; Member, Human Oncology and Pathogenesis Program

Professor

Physician-scientist Emily Cheng focuses on the molecular mechanisms of cell death and their implications in tumorigenesis and cancer therapy, with primary emphasis on lung and kidney cancers.
MD, Taipei Medical University
PhD, Johns Hopkins University School of Medicine

chenge1@mskcc.org: Email Address
646-888-3258: Office Phone

Members

Song Han

Research Assistant

Kai Xi Lin

Research Technician

Amrita Mangalvedhekar

Senior Research Scientist

Allison Moyer

Shriram Ramani

Research Technician

Danielle Richards

Program Assistant

Shaoyuan Yang

Research Fellow

Lab Alumni

Gregory Bean
Graduate Research Assistant

Hui-Chen Chen

Research Fellow

Beatrice D'Orsi

Research Fellow

Yafen Huang, PhD — Yafen Huang
Research Fellow

Paul Jeng

Graduate Student

Chung Ping Liao, PhD — Chung Ping Liao
Research Fellow

Yogesh Tengarai Ganesan

Research Technician

Akane Yamauchi

Research Fellow

Kota Ishizawa

Research Fellow

Sonali Sinha

Kosuke Tanaka

Yuchen Xie
Data Scientist at Audible, Inc., Newark, NJ

Wudan Yan

Graduate Student

Ju Zhou

Lab Affiliations

Achievements

Distinguished Investigator Award, Washington University School of Medicine (2010)
Searle Scholar Award (2005)
Howard Temin Award, National Cancer Institute (2003)

Open Positions

Career Opportunities

Apply now

Get in Touch

chenge1@mskcc.org

Lab Head Email
646-888-3258

Office Phone
646-888-3266

Office Fax

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Emily H. Cheng discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures